{
    "patient": {
        "Name": "Brittany Munoz",
        "DateOfBirth": "1933-09-18",
        "Sex": "Female",
        "Diagnosis": "Adenocarcinoma",
        "BodyPart": "Pancreatic",
        "Physician": "Dr. Timothy Lee",
        "TreatingInstitution": "Collins-Wilson"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Pancreatic",
            "CollectedDate": "2024-02-21",
            "ReceivedDate": "2024-02-23",
            "TumorPercentage": "23%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-02-24",
            "ReceivedDate": "2024-02-29"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "CCND3",
                "DNA Alteration": "c.766_776del11",
                "GeneMutation": "p.R256fs*64 Spliceregionvariant-GOF",
                "VariantAlleleFraction": "30.5%"
            },
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Frameshift-LOF",
                "VariantAlleleFraction": "32.25%"
            },
            {
                "Gene": "TEK",
                "DNA Alteration": "c.1354A>G",
                "GeneMutation": "p.N452D Nonsense-LOF",
                "VariantAlleleFraction": "13.57%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "JAK3",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N452D Nonsense-GOF",
                "VariantAlleleFraction": "9.82%"
            },
            {
                "Gene": "ZEB2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.L857P Frameshift-LOF",
                "VariantAlleleFraction": "5.12%"
            },
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N452D Nonsense-GOF",
                "VariantAlleleFraction": "12.0%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "PTPN11",
            "IDH1"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "42 m/Mb",
            "Tmbpercentile": "30%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Equivocal"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.97T>C",
                "GeneMutation": "p.S33C Spliceregionvariant-LOF",
                "VariantAlleleFraction": "1.6%"
            },
            {
                "Gene": "FGFR2",
                "DNA Alteration": "c.1645A>C",
                "GeneMutation": "p.Y375C Spliceregionvariant-LOF",
                "VariantAlleleFraction": "2.25%"
            },
            {
                "Gene": "HDAC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.E455fs*7 Nonsense-GOF",
                "VariantAlleleFraction": "5.51%"
            },
            {
                "Gene": "RB1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.F650S Frameshift-GOF",
                "VariantAlleleFraction": "3.12%"
            },
            {
                "Gene": "NT5C2",
                "DNA Alteration": "c.1100G>A",
                "GeneMutation": "p.R367Q Spliceregionvariant-LOF",
                "VariantAlleleFraction": "6.51%"
            },
            {
                "Gene": "HSD3B1",
                "DNA Alteration": "c.1100=",
                "GeneMutation": "p.T367= Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "1.25%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Frameshift-GOF",
                "VariantAlleleFraction": "7.29%"
            },
            {
                "Gene": "NTRK1",
                "DNA Alteration": "c.1792C>T",
                "GeneMutation": "p.G607V Spliceregionvariant-LOF",
                "VariantAlleleFraction": "3.6%"
            },
            {
                "Gene": "FGFR3",
                "DNA Alteration": "c.1111A>T",
                "GeneMutation": "p.G380R Frameshift-LOF",
                "VariantAlleleFraction": "9.89%"
            },
            {
                "Gene": "PIK3CA",
                "DNA Alteration": "c.3141T>G",
                "GeneMutation": "p.E542G Spliceregionvariant-LOF",
                "VariantAlleleFraction": "6.39%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "CCND3"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "CCND3",
                "DNA Alteration": "c.766_776del11",
                "GeneMutation": "p.R256fs*64 Spliceregionvariant-GOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "30.5%"
            },
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Frameshift-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "32.25%"
            },
            {
                "Gene": "TEK",
                "DNA Alteration": "c.1354A>G",
                "GeneMutation": "p.N452D Nonsense-LOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "13.57%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "JAK3",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N452D Nonsense-GOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "9.82%"
            },
            {
                "Gene": "ZEB2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.L857P Frameshift-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "5.12%"
            },
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N452D Nonsense-GOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "12.0%"
            }
        ]
    },
    "clinical history": {
        "Date": "2024-02-17"
    },
    "other": {
        "ReportId": "5628",
        "ReportDate": "2024-02-26",
        "SignedBy": "Timothy Lee",
        "Supervisor": "Dr. Paula Wilson"
    }
}